Cure GM1 to Collaborate with xCURES for Natural History Study Pilot
Cure GM1, a 501(c)(3) nonprofit organization located in Albany, CA, USA is proud to announce…
-
-
Over $461K Grant toward Enzyme Replacement Therapy with TEGA Therapeutics
TEGA Therapeutics, Inc. has been awarded a Phase I Small Business and Innovative Research (SBIR)…
-
Gelb Laboratory Publishes Third GM1 Newborn Screening Paper
Cure GM1 provided seed funding for, and families from the GM1 community provided dried blood…
-
Asia’s Story
This is the story of Asia, a little princess born on December 6, 2020. Asia…
-
Luigi’s story
Hi friends, my name is Luigi. I’m Italian, and I’ll be 3 in October. Unfortunately…
-
2022 Cure GM1 Impact Report – Impact in 2022 and Beyond
Our summary of impact in 2022 is now available to read. After some time reflecting,…
-
Diego’s Story
Diego was born on June 29, 2021 in Imola, a small town in Italy. We…
-
The Voice of the Patient Report from the GM1 Gangliosidosis Externally-Led Patient-Focused Drug Development Meeting (EL-PFDD)
You can now download and read the touching and impactful summary of input from GM1…
-
About the GM1 Gangliosidosis Externally-Led Patient-Focused Drug Development (EL-PFDD) Meeting with FDA
The GM1 Externally-Led Patient-Focused Drug Development Meeting (EL-PFDD) was held on Friday, October 14 as…